Kessler L, Tritschler S, Bohbot A, Sigrist S, Karsten V, Boivin S, Dufour P, Belcourt A, Pinget M
Department of Endocrinology-Diabetology, University Hospital, Strasbourg, France.
Diabetes Care. 2001 Feb;24(2):302-7. doi: 10.2337/diacare.24.2.302.
The purpose of this study was to evaluate the activation of macrophages in type 1 diabetic patients during peritoneal insulin delivery with an implantable pump against two types of insulin: that which was collected from the pump reservoir and that which came straight fromn the bottle (i.e., vial insltlin). Macrophage activation was studied in patients with and without cathcter obstruction and compared with activation in healthy subjects.
Human insulin (21 PH, 400 U/ml; Hoescht) was collected from the pump reservoir (Minimed) of diabetic patients with (n = 3) or without (n = 7) catheter obstruction, as assessed by histological examination of the catheter tip. Monocytes were obtained from venous blood samples from both kinds of diabetic patients and from healthy subjects (n = 5) and were differentiated into monocyte-derived macrophages in culture. Their chemotaxis and tumor necrosis factor-alpha (TNF-alpha) release were studied with respect to both types of insulin, as previously stated. Formyl-methionyl-leucyl-phenylalanine (fMLP) and lipopolysaccharide (LPS) were used as controls.
Neither insulin recovered from the pump reservoir nor vial insulin proved chemotactic to macrophages from either healthy subjects or those diabetic patients with and without catheter obstruction. The migration toward fMLP of macrophages from patients presenting a catheter obstruction was significantly higher than that observed with macrophages from either diabetic patients without obstruction or healthy subjects, the chemotactic index (mean +/- SD) was 3.81 +/- 0.36 vs. 2.30 +/- 0.89 and 2.60 +/- 0.80, respectively (P < 0.05). LPS significantly stimulated the TNF-alpha secretion of macrophages from diabetic subjects with a catheter obstruction, whereas both native and reservoir-recovered insulin had no effect on this release (144.83 +/- 67.25 vs. 5.15 +/- 2.93 and 5.27 +/- 2.43 pg/ml, P < 0.001).
The human insulin used in implantable pumps, regardless of how long it had remained in the pump reservoir, did not induce macrophage activation in diabetic patients treated through intraperitoneal insulin delivery. In some of these diabetic patients, catheter obstruction could be explained by their high capacity of macrophage chemotaxis.
本研究旨在评估1型糖尿病患者在使用植入式泵进行腹膜内胰岛素输注时,两种胰岛素对巨噬细胞的激活作用:一种是从泵储液器中收集的胰岛素,另一种是直接从瓶中取出的胰岛素(即瓶装胰岛素)。研究了有和没有导管阻塞的患者的巨噬细胞激活情况,并与健康受试者的激活情况进行比较。
通过对导管尖端进行组织学检查,评估有(n = 3)或无(n = 7)导管阻塞的糖尿病患者的泵储液器(美敦力)中收集人胰岛素(21 PH,400 U/ml;赫斯特)。从这两类糖尿病患者以及健康受试者(n = 5)的静脉血样本中获取单核细胞,并在培养中使其分化为单核细胞衍生的巨噬细胞。如前所述,研究了它们对两种胰岛素的趋化性和肿瘤坏死因子-α(TNF-α)释放情况。使用甲酰甲硫氨酰亮氨酰苯丙氨酸(fMLP)和脂多糖(LPS)作为对照。
从泵储液器中回收的胰岛素和瓶装胰岛素对健康受试者或有和无导管阻塞的糖尿病患者的巨噬细胞均无趋化作用。有导管阻塞的患者的巨噬细胞对fMLP的迁移明显高于无阻塞的糖尿病患者或健康受试者的巨噬细胞,趋化指数(均值±标准差)分别为3.81±0.36、2.30±0.89和2.60±0.80(P < 0.05)。LPS显著刺激有导管阻塞的糖尿病受试者的巨噬细胞分泌TNF-α,而天然胰岛素和从储液器中回收的胰岛素对此释放均无影响(分别为144.83±67.25、5.15±2.93和5.27±2.43 pg/ml,P < 0.001)。
植入式泵中使用的人胰岛素,无论在泵储液器中留存了多长时间,在通过腹膜内胰岛素输注治疗的糖尿病患者中均未诱导巨噬细胞激活。在一些此类糖尿病患者中,导管阻塞可能与其巨噬细胞的高趋化能力有关。